Ben Auspitz has worked in pharmaceuticals and life-science for over fifteen years, both in industry and as a consultant. Most recently before joining Fidelity, he served as Therapeutic Area Head for Immuno-Inflammatory products at CombinatoRx Inc. during its growth from an angel-backed start-up to a publicly-listed company (NASDAQ: CRXX). In this role, he oversaw the advancement of seven programs from assay stage into phase II human clinical studies, and was co-inventor on 15 product patents. He also served as Director for Corporate Strategy at CombinatoRx, where he was responsible for product in-licensing, new business development, and the build-out and $20M financing of an infectious disease subsidiary. His consulting experience has included work in clinical development, product launch, M&A, and medical marketing. Sample projects include sales force optimization and managed markets strategy for Celebrex, the first-in-class COX-2 inhibitor, and clinical development strategy for gene-therapy, protein, and small molecule products.
He holds a B.A. from Harvard University.
Mr. Auspitz serves on the Board of Directors of Ligocyte Pharmaceuticals, BIKAM Pharmaceuticals, and Ultragenyx Pharmaceutical.